A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma
Phase of Trial: Phase I
Latest Information Update: 18 Mar 2016
At a glance
- Drugs ASG 5ME (Primary)
- Indications Gastric cancer; Pancreatic cancer
- Focus Adverse reactions; First in man
- 18 Mar 2016 Results published in the Investigational New Drugs
- 07 May 2013 Status changed from recruiting to active, no longer recruiting, according to a Seattle Genetics media release.
- 25 Jan 2013 Enrollment of patients with pancreatic ductal adenocarcinoma has been completed according to a Seattle Genetics media release. Enrollment of patients with relapsed/refractory gastric adenocarcinoma is ongoing.